ATYR
ATYR
NASDAQ · Biotechnology

Atyr Pharma Inc

$0.60
+0.03 (+5.37%)
As of Jun 30, 10:35 PM ET ·
Financial Highlights (FY 2026)
Revenue
207.2K
Net Income
-82,571,913
Gross Margin
Profit Margin
-39,009.5%
Rev Growth
-73.7%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 60.1% 60.1%
Operating Margin -40,856.3% -36,770.7% 17.4% 17.8%
Profit Margin -39,009.5% -37,059.0% 18.1% 18.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 207.2K 786.3K 11.28M 11.12M
Gross Profit 6.78M 6.68M
Operating Income -84,646,123 -289,113,892 1.97M 1.97M
Net Income -82,571,913 -282,029,304 2.04M 2.05M
Gross Margin 60.1% 60.1%
Operating Margin -40,856.3% -36,770.7% 17.4% 17.8%
Profit Margin -39,009.5% -37,059.0% 18.1% 18.5%
Rev Growth -73.7% -73.7% +22.8% +18.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 356.0K 356.0K 10.29M 11.21M
Total Equity 26.97M 26.97M 51.15M 53.31M
D/E Ratio 0.01 0.01 0.20 0.21
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -85,741,780 -309,125,962 2.88M 2.97M
Free Cash Flow 1.40M 1.41M